TY - JOUR
T1 - Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
AU - Verhoef, Talitha I.
AU - Redekop, William K.
AU - van Schie, Rianne Mf
AU - Bayat, Samira
AU - Daly, Ann K.
AU - Geitona, Mary
AU - Haschke-Becher, Elisabeth
AU - Hughes, Dyfrig A.
AU - Kamali, Farhad
AU - Levin, Lars-Åke
AU - Manolopoulos, Vangelis G.
AU - Pirmohamed, Munir
AU - Siebert, Uwe
AU - Stingl, Julia C.
AU - Wadelius, Mia
AU - de Boer, Anthonius
AU - Maitland-van der Zee, Anke-Hilse
AU - AUTHOR GROUP
AU - Barallon, Rita
AU - Daly, Ann
AU - der Zee, Anke-Hilse Maitland-van
AU - Redekop, Ken
AU - Stingl, Julia
AU - Rosendaal, Frits R.
PY - 2012
Y1 - 2012
N2 - Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy of dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin derivatives). The anticipated degree of improvement in the safety of anticoagulation with coumarins through genotyping may vary depending on the quality of patient care, which varies both with and among countries. The management and the cost of anticoagulant care can therefore influence the cost effectiveness of genotyping within any given country. In this article, we provide an overview of the cost effectiveness of pharmacogenetics-guided dosing of coumarin derivatives. We describe the organization of anticoagulant care in the UK, Sweden, The Netherlands, Greece, Germany and Austria, where a genotype-guided dosing algorithm is currently being investigated as part of the EU-PACT trial. We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries
AB - Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy of dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin derivatives). The anticipated degree of improvement in the safety of anticoagulation with coumarins through genotyping may vary depending on the quality of patient care, which varies both with and among countries. The management and the cost of anticoagulant care can therefore influence the cost effectiveness of genotyping within any given country. In this article, we provide an overview of the cost effectiveness of pharmacogenetics-guided dosing of coumarin derivatives. We describe the organization of anticoagulant care in the UK, Sweden, The Netherlands, Greece, Germany and Austria, where a genotype-guided dosing algorithm is currently being investigated as part of the EU-PACT trial. We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries
U2 - https://doi.org/10.2217/PGS.12.124
DO - https://doi.org/10.2217/PGS.12.124
M3 - Review article
C2 - 22966889
SN - 1462-2416
VL - 13
SP - 1405
EP - 1417
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 12
ER -